EASY ACCESS AND AFFORDABILITY
FOR YOUR PATIENTS

PRESCRIBING XEPI® (ozenoxacin) CREAM, 1%

Your patients can get Xepi® via direct home delivery from a specialty pharmacy.
 

Samples (3 g) are available for immediate use so patients can begin treatment before leaving your office

Fulfilled by a specialty pharmacy

Xepi® is only available by prescription through a specialty pharmacy

XEPI® INFORMATION REQUEST FORM

Only requests by qualified healthcare providers will be processed. Consumers should visit our consumer site at www.xepicream.com.

Please view our Privacy Policy.

†Required fields.

Specialty pharmacy fulfillment


Xepi® is only available by prescription through a specialty pharmacy. A detailed independent specialty pharmacy may coordinate shipping of a 30-g tube of Xepi® directly to a patient's home.

Specialty distributor locator


Find a dedicated specialty pharmacy near your patient that carries Xepi®. Then, send an instant rebate form to the specialty pharmacy of your patient's choice.

This offer is not valid if you are eligible for reimbursement of this product, in whole or in part, under Medicare, Medicaid, Medigap, VA, DOD or government-subsidized clinics or similar federal or state programs. Uninsured, cash paying patients are also not eligible to participate in the Biofrontera Patient Savings Program. Only patients with commercial insurance are eligible to participate in the Biofrontera Patient Savings Program to reduce out-of-pocket expenses on eligible prescriptions of Xepi® at participating pharmacies in the United States. Taxes and shipping fees may apply. This offer is limited to one time per patient in any 30-day period. This offer cannot be combined with any other offer. This offer is void where prohibited by law. Biofrontera Inc. reserves the right to rescind, revoke, or amend this offer at any time, without notice.

Patient Instructions: Eligible patients purchasing Xepi® with a valid prescription at participating pharmacies in the United States are automatically entitled to participate in the Biofrontera Patient Savings Program. Commercially-insured patients will pay as little as $35 per prescription for up to 4 prescription fills per year of Xepi® (containing 1- 30g tube). Maximum benefit limits apply. Any remaining out-of-pocket costs will be the patient’s responsibility. By utilizing this program, patient acknowledges and agrees to comply with the terms and conditions as set forth above.

* Excludes all state taxes and applicable fees; maximum benefits apply.

 

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE

Xepi® (ozenoxacin) Cream, 1% is indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older.

Apply a thin layer of Xepi® topically to the affected area twice daily for 5 days. Affected area may be up to 100 cm2 in adult and pediatric patients 12 years of age and older or 2% of the total body surface area and not exceeding 100 cm2 in pediatric patients less than 12 years of age.

IMPORTANT SAFETY INFORMATION

Xepi®, containing 1% ozenoxacin, is for topical use only. Not for ophthalmic, oral, intranasal or intravaginal use.

Apply a thin layer of Xepi® topically to the affected area twice daily for 5 days. Affected area may be up to 100 cm2 in adult and pediatric patients 12 years of age and older or 2% of the total body surface area and not exceeding 100 cm2 in pediatric patients less than 12 years of age.

Potential for Microbial Overgrowth: Prolonged use of Xepi® may result in overgrowth of nonsusceptible bacteria and fungi. If such infections occur, discontinue use and institute alternative therapy.

Adverse reactions (rosacea and seborrheic dermatitis) were reported in 1 adult patient treated with Xepi®.

There are no available data on the use of Xepi® in pregnant women to inform a drug associated risk. No data are available regarding the presence of ozenoxacin in human milk, and the effects of ozenoxacin on the breastfed infant or on milk production.

The safety and effectiveness of Xepi® in the treatment of impetigo have been established in pediatric patients 2 months to 17 years of age. The safety profile of Xepi® in pediatric patients 2 months and older was similar to that of adults.

The safety and effectiveness of Xepi® in pediatric patients younger than 2 months of age have not been established.

Please read the US Full Prescribing Information for Xepi® available at https://www.xepicream.com/PI.

You are encouraged to report side effects of Xepi®. Please contact Biofrontera Inc. at 1-844-829-7434 or FDA at 1-800-332-1088 or www.fda.gov/medwatch.